About Bonti
Bonti is a Healthcare company based in Newport Beach (United States) founded in 2015 by Susan Abushakra and Mike Jarpe, and was acquired by Allergan in September 2018. Botulinum neurotoxins are developed for musculoskeletal pain treatment. Bonti has raised $36.05 million across 5 funding rounds from investors including SVB, Allergan and City Hill. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its competitors include Flexion Therapeutics, Eliem Therapeutics and Zogenix; 3 of its 3 listed competitors have raised funding.
Company details
Bonti was founded in 2015 in Newport Beach, United States, as a clinical-stage biotechnology firm. Botulinum neurotoxins are developed using a proprietary platform for therapeutic and aesthetic uses. The lead candidate, EB-001, a serotype E botulinum neurotoxin, is advanced for post-surgical and non-surgical musculoskeletal pain. Muscle hyperactivity, identified as a primary pain driver, is addressed through this approach in ongoing clinical efforts.
Funding Insights of Bonti
Bonti has successfully raised a total of $36.05M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $15.5 million completed in January 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $36.05M
- Total Rounds 5
- Last Round Series C — $15.5M
- First Round $8.84M
(Sep 2015)
- Investors Count 7
All 5 funding rounds of Bonti with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2018 | $15.5M | Series C | – | City Hill | – |
| Jun 2017 | Series B | – | Viva Ventures Biotech Fund | – | |
| Apr 2017 | $11.71M | Series B | – | RBV Capital | |
| Dec 2015 | $2M | Debt – Conventional | – | – | |
| Sep 2015 | $8.84M | Series A | – | City Hill | – |
8 investors in total: 8 institutional.
Investors in Bonti
Bonti has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Allergan and City Hill.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm and foundation focused on biotech, cleantech, and media & entertainment, education, and more | cityhill.com | San Diego, United States | ||
| vivaventuresbiotech.com | ||||
A life sciences venture capital fund is managed. | 2014 | rbvcapital.com | ||
Private equity investments are managed by this USA-based firm. | coltventures.com | Dallas, United States | ||
| jmcrpartners.com | ||||
Private equity and early-stage venture capital firm investing primarily in Chinese companies | highlightcapital.com | Shanghai, China | ||
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
A portfolio of generic medicines is developed and manufactured. | 1948 | allergan.com | Madison, United States |
Investor details for Bonti
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bonti
2 people are tracked at Bonti (2 in leadership).
| Name | Role | Group |
|---|---|---|
Susan Abushakra | Co-Founder & CMO | Leadership |
Mike Jarpe | Co-Founder | Leadership |
Complete people profiles for Bonti
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Bonti
4 dated milestones of Bonti across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Bonti is founded.
- Funding First funding round of $8.8M.
- Funding Latest funding round, Series C, of $15.5M.
- Exit Acquired by Allergan.
Competitors of Bonti
Bonti has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Eliem Therapeutics and Zogenix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. | |
| zogenix.com | 2006 | Emeryville, United States | $149.06M | 159 | Drug delivery systems for CNS disorders and pain are developed. |
Detailed competitors of Bonti
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Pain Management
3 companies that operate in the same segment as Bonti (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bonti
Complete news archive for Bonti
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bonti
Bonti was founded in 2015.
Bonti is headquartered in Newport Beach, United States. It is registered at Newport Beach, California, United States.
Bonti is a funded company, having raised a total of $36.05M across 5 funding rounds to date. The company's 1st funding round was a Series A of $8.84M, raised on Sep 2015.
Bonti was founded in 2015 in Newport Beach, United States, as a clinical-stage biotechnology firm. Botulinum neurotoxins are developed using a proprietary platform for therapeutic and aesthetic uses. The lead candidate, EB-001, a serotype E botulinum neurotoxin, is advanced for post-surgical and non-surgical musculoskeletal pain. Muscle hyperactivity, identified as a primary pain driver, is addressed through this approach in ongoing clinical efforts.
Bonti's top competitors include Flexion Therapeutics, Zogenix and Eliem Therapeutics.
Bonti has 8 investors. Key investors include SVB, Allergan, City Hill, Viva Ventures Biotech Fund, and RBV Capital.
Yes. Bonti was acquired by Allergan in September 2018.